Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply Dr Kuschner is concerned that the dose of aspirin selected for our lung injury prevention trial may have been subtherapeutic and poorly informed based on the supporting literature cited.1,2 A specific highlighted concern is the notable difference in study populations when comparing those previously studied with those who were enrolled in this trial (eg, healthy volunteers vs those with acute illness and risk for ARDS). Such concerns, in addition to the well-documented potential for aspirin resistance, greatly influenced the study design. Indeed, the decision to provide an initial loading dose of aspirin (325 mg) was driven by the desire to mitigate the potential for insufficient dosing of the study medication while also attempting to balance potential risks for adverse events associated with aspirin administration.
Kor DJ, Gong MN, Levy BD. Aspirin and Acute Respiratory Distress Syndrome—Reply. JAMA. 2016;316(12):1318. doi:10.1001/jama.2016.12327
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: